Later this year, Bristol Myers Squibb will begin to lose billions of dollars in revenue when generic versions of its top-selling cancer drug Revlimid become available. But with six recent drug launches and another three drugs heading for the market this year, Bristol expects to offset the lost Revlimid revenue and continue to grow through the end of the decade.
Fresh off a presentation at the J.P. Morgan Healthcare Conference, Bristol CEO Giovanni Caforio sat down with STAT last week to discuss his company’s outlook and plans for more business development, including acquisitions.
Below are excerpts from the conversation, edited for clarity and length.
About the Author Reprints
